Cell Therapy Tools for Cartilage Repair From Osteoarthritic Knee Joint of Elderly
18.6.2020 08:34:00 EEST | Business Wire | Press release
A break through feat of growing pluripotency expressing cells from osteoarthritis (OA) affected cartilage tissue of knee joints of elderly has been reported by orthopedicians and cell culture experts led by Dr Shojiro Katoh, President, Edogawa Hospital. OA affects, knee joints of millions globally and those with severe disease, undergo Total Knee Arthroplasty (TKA), in which damaged cartilage is replaced with artificial knee prosthesis. Dr Katoh, during TKA surgery, took portions of the damaged tissue, which otherwise is discarded, isolated chondrocyte cells in tissue engineering lab, and could culture them as fully reorganized healthy cartilage tissue, expressing biomarkers relevant to pluripotency.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200617005880/en/
"Pluripotency expressing cells grown from osteoarthritis affected knee joint, open doors to a spectrum of novel solutions to address cartilage damage," says Dr. Shojiro Katoh, President, Edogawa Hospital, Tokyo, Japan. (Photo: Business Wire)
Cartilage of the knee joint acts as a cushion between bones of the thigh and leg and absorbs the body weight. When cartilage is damaged due to sports injury, trauma or wear and tear, it causes joint pain and disability. In early stage of the disease, Autologous Chondrocyte Implantation (ACI) or Matrix Assisted Chondrocyte Implantation (MACI) are practiced. Such cell therapies use patient’s own cartilage cells, harvested from healthy, non-weight bearing area, grown in lab, and transplanted to replace the damaged tissue, to restore functionality.
"This could probably be the world’s first report of Osteoarthritis tissue, yielding cells expressing pluripotency markers," said Dr. Katoh, citing their publication in Regenerative Therapy Journal (https://www.sciencedirect.com/science/article/pii/S2352320420300274), also presented in the 19th Japanese society for regenerative medicine meeting. "Our technique may help utilize OA affected cartilage, discarded as biomedical waste, as a source of tools of cell therapies viz., cells, cell secreted growth factors, and exosomes to repair cartilage defects in regenerative medicine," he added.
Edogawa hospital, located in eastern Tokyo, has many senior citizens. "Contrary to the age-old belief that Wisdom is the strength of elders, this research finding has made me humble, to learn about nature’s hidden strength in their physical intricacies too, fueling our enthusiasm," said Dr Katoh adding a philosophical humility to his accomplishment. His Edogawa Evolutionary Lab of Science (EELS), having confirmed hyaline phenotype is now evaluating miRNA-140 and Hyaluronan expression of chondrocytes.
This technology has a potential to solve cartilage damage of approximately 12 million people annually worldwide, according to JBM Inc, and GN Corporation, co-applicants to a patent and research partners to EELS.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200617005880/en/
Contact information
Samuel JK Abraham
GN Corporation
info@gncorporation.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetApp Helps Customers Accelerate Adoption of Latest VMware Cloud Foundation Innovations2.9.2026 23:30:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, announced new capabilities in NetApp ONTAP® have been tested and validated to support VMware Cloud Foundation (VCF) 9.1, giving customers an optimized and secure data infrastructure foundation for their private and hybrid clouds. By combining the advanced capabilities of VCF 9.1 with cost-effective and enterprise data management with built-in security features from NetApp, including safeguarding data against ransomware attacks with rapid recovery, mutual customers can lower costs and accelerate the deployment of their AI software into production. VMware Cloud Foundation 9.1 provides enterprises with a unified private cloud platform for running both traditional and modern workloads. NetApp's solutions are tested and validated to support VCF 9.1 environments, enabling mutual customers to immediately begin taking advantage of VCF 9.1 innovations when they upgrade, with a data infrastructure layer already proven to work w
Venture Global Announces Closing of $3,000,000,000 364-Day Senior Secured Revolving Credit Facility2.9.2026 23:30:00 EEST | Press release
Venture Global, Inc. (“Venture Global”) announced today that its subsidiary Venture Global LNG, Inc. (“VGLNG”) has entered into a new, $3,000,000,000 364-day revolving credit facility (the “Facility”). Venture Global expects to use the proceeds from borrowings under the Facility for general corporate purposes of VGLNG and its subsidiaries, including to fund certain project costs for the CP2 and Plaquemines bolt-on expansions prior to their respective FIDs. Bank of America, N.A. served as Coordinating Lead Arranger and Sole Bookrunner and will also serve as Administrative Agent. BBVA, Goldman Sachs, ING, J.P. Morgan, Mizuho, MUFG, NBC, RBC, Scotia, SMBC, U.S. Bank, and Wells Fargo served as Coordinating Lead Arrangers and Barclays, Santander, and Deutsche Bank served as Joint Lead Arrangers. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Vent
Invivoscribe Begins Commercial Shipments of PrepQuant ™ Systems, Enabling High-Sensitivity Sample Preparation for MRD Testing2.9.2026 22:31:00 EEST | Press release
Invivoscribe®, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced that commercial shipments of the PrepQuant™ System have begun in North America. First unveiled at the American Association for Cancer Research Annual Meeting in April 2026, PrepQuant is now being delivered to customers, marking the platform's progression from development and validation into commercial deployment. The commercial milestone extends Invivoscribe's capabilities into laboratory instrumentation and addresses a critical bottleneck in highly sensitive molecular testing: efficiently recovering, concentrating, and quantifying DNA from larger blood and plasma inputs. PrepQuant is assay agnostic, designed to produce concentrated genomic DNA and cell-free DNA (cfDNA) suitable for a full range of downstream molecular workflows, including MRD assays intended to detect very low levels of residual disease. MRD Sensitivity Starts Before the Assay As MRD testing moves tow
C.H. Guenther Opens Centre of Excellence in Coventry, UK to Accelerate Bakery Innovation and Support Future Manufacturing Growth Across UK and Europe2.9.2026 19:00:00 EEST | Press release
C.H. Guenther & Son LLC (“C.H. Guenther” or “CHG”), a leading food manufacturer, has opened a new Centre of Excellence (the “Centre”) at its flagship Coventry bakery, creating a dedicated innovation and customer collaboration hub designed to accelerate the development of premium bakery products across the UK and Europe. The new facility has been designed to support CHG’s customers including leading global quick service restaurants, foodservice operators and retailers as they develop, test and refine new bakery products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260902696890/en/ The purpose-built, 172-square-metre Centre of Excellence brings together a commercial-scale bakery, customer demonstration kitchen, sensory evaluation facilities, innovation suite and dedicated collaboration spaces in one specialized location. Designed to support and accelerate product development from concept through to commercial manufacturing,
Record Asset Management Enters New Phase of Growth2.9.2026 18:35:00 EEST | Press release
Record Asset Management GmbH (“RAM”), a subsidiary of London-listed Record plc (“Record” or the “Group”), is pleased to announce that it is now operating cashflow positive, thereby marking a transition from its investment phase into a growth business within the Group, and a significant milestone towards sustainable profitability. RAM is the European asset management arm of Record, the London-listed specialist investment group managing USD 122 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom the Group has built long-standing relationships through its focus on bespoke investment and risk management solutions. RAM was established as a sister company to Record’s core currency business and obtained its BaFin license in 2022. RAM has grown rapidly in the last two years and has developed into a diversified private markets platform with dedicated infrastructure e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
